Clinical trial
SPC2996 in Chronic Lymphocytic Leukaemia
NCT00285103 · Santaris Pharma A/S, Industry · Completed
Key facts
| NCT number | NCT00285103 |
|---|---|
| Title | SPC2996 in Chronic Lymphocytic Leukaemia |
| Official title | An Open-labelled, International, Multicenter, Dose Escalating, Phase I/II Study of SPC2996,an LNA Antisense Molecule Against Bcl-2, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia |
| Lead sponsor | Santaris Pharma A/S, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | SPC2996 |
| Enrollment | 46 |
| Start date | Jun 1, 2005 |
| Completion | Dec 1, 2007 |
| First posted | Feb 1, 2006 |
| Last update posted | Feb 2, 2011 |
| Countries | Denmark, France, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: